Vermillion Granted US Patent Supporting Vasclir Diagnostic; Begins Intended-Use Study for Test
January 14, 2011
Vermillion Granted US Patent Supporting Vasclir Diagnostic; Begins Intended-Use Study for Test
The patent covers "biomarker combinations that include B2-microglobulin for the diagnosis and management of peripheral artery disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay," the company said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Vermillion Granted US Patent Supporting PAD Biomarker
September 17, 2010 / ProteoMonitor - Vermillion Posts $344,000 in Q2 Revenues, Including First Sales of OVA1 Test
August 13, 2010 / ProteoMonitor - Vermillion Plans to Raise Up to $17.3M in Stock Offering
January 21, 2011 / ProteoMonitor - Vermillion Performs 3,920 OVA1 Tests in Q2, But Revenues Fall 9 Percent on Drop in Licensing Income
August 5, 2011 / ProteoMonitor - Vermillion Posts $431K in Q1 Revenue, Anticipates Two Peer-Reviewed Articles on OVA1
May 13, 2011 / ProteoMonitor